<DOC>
	<DOC>NCT02604537</DOC>
	<brief_summary>The purpose of this study is to determine if corticosteriod injection modifies the natural course of de Quervain tendinopathy compared to a toradol injection.</brief_summary>
	<brief_title>Celestone Versus Ketorolac Injection for the Treatment of DeQuervains Tenosyovitis</brief_title>
	<detailed_description />
	<mesh_term>Tendinopathy</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<mesh_term>Ketorolac</mesh_term>
	<mesh_term>Ketorolac Tromethamine</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Epinephrine</mesh_term>
	<mesh_term>Racepinephrine</mesh_term>
	<mesh_term>Epinephryl borate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<criteria>Diagnosis of deQuervain tendinopathy Understands the local language and is willing and able to follow the requirements of the protocol Understands the informed consent and signs the institutional review board/independent ethics committee (IRB/IEC) approved informed consent form Patients who have an allergy to lidocaine, celestone, or ketorolac, NSAIDS, or ASA Patients who have an adverse reaction to lidocaine, celestone, or ketorolac (such as severe elevation of blood sugars in diabetics that caused medical complication) Patients who have received a prior steriod injection within the past three months Patients who have had a prior ipsilateral surgery for De!uervains Tenosyovitis Patients that have a skin lesion at the location of injection (such as trauma, eczema, rash) Patients who have a current infection at the location of injection Patients who have had iontophoresis within three months Patients who are breast feeding, pregnant, or who plan to become pregnant in the next six months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>